Resetting autoimmune disease with CAR cell therapies
CAR T cell therapy shows promise as an immune reset strategy for severe autoimmune diseases that don't respond to conventional treatments.
This Nature Medicine review by Schett and Xu synthesizes the rapidly growing evidence for CAR T cell therapy as an 'immune reset' strategy in autoimmune diseases, covering CD19- and BCMA-directed constructs, current trial evidence, and the key distinction between autologous and allogeneic approaches. The review addresses high unmet need populations with refractory autoimmune diseases and provides a clinical roadmap for a field expanding beyond oncology.
What the study was
- Study design
- Comprehensive narrative review
- Population
- Patients with autoimmune diseases (systemic lupus, dermatomyositis, systemic sclerosis, others)
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Nat Med
Why it surfaced
Nature Medicine review on CAR-T for autoimmune diseases — an expanding paradigm with major clinical implications. Dual authors from leading CAR-T centers. NOVEL_TREATMENT flag triggers HIGH. unsolicited_find=true as this is non-oncology application of CAR-T.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.